Trade Taysha Gene Therapies Inc - TSHA CFD

Trade Taysha Gene Therapies Inc - TSHA CFD

About Taysha Gene Therapies Inc

Taysha Gene Therapies, Inc. is a gene therapy company focused on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. Its product candidates include: TSHA-101, which is being developed for the treatment of GM2 gangliosidosis; TSHA-118, which is a AAV9 viral vector that expresses human codon-optimized Ceroid Lipofuscinosis Neuronal 1 complementary deoxyribonucleic acid under control of the chicken b-actin hybrid promoter; TSHA-102, which is being developed for the treatment of Rett syndrome; TSHA-103, which is being developed for the treatment of Solute Carrier Family 6 Member 1 (SLC6A1) haploinsufficiency disorder, and TSHA-104, which is being developed for the treatment for Surfeit locus 1.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Taysha Gene Therapies Inc revenues was not reported. Net loss increased from $41.7M to $124.1M. Higher net loss reflects Interest expense increase from $28K to $737K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.21 to -$3.30.